Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone.
D000477:Alkylating Agents / Q000627:therapeutic use*; D000686:Amyloidosis / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007072:Immunoglobulin D / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007147:Immunoglobulin Light Chains / Q000032:analysis*; D007075:Immunoglobulin M / Q000032:analysis; D007145:Immunoglobulin kappa-Chains / Q000032:analysis*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*
D000477:Alkylating Agents; D007070:Immunoglobulin A; D007072:Immunoglobulin D; D007074:Immunoglobulin G; D007147:Immunoglobulin Light Chains; D007075:Immunoglobulin M; D007145:Immunoglobulin kappa-Chains; D003520:Cyclophosphamide; D008558:Melphalan; D011241:Prednisone